Singapūra - angļu - HSA (Health Sciences Authority)

abbvie pte. ltd. - palivizumab - injection, powder, for solution - 100 mg/vial (100mg/ml) - palivizumab 100 mg/vial (100mg/ml)

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - ranibizumab -

Singapūra - angļu - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - ranibizumab - injection, solution - ranibizumab 1.65mg/0.165ml

Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ranibizumab 10 mg/ml - 10 mg/ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - palivizumab - solution for injection - 100mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - palivizumab - solution for injection - 100mg/1ml

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - ranibizumab -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab -

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

swedish orphan biovitrum ab (publ) - palivizumab (unii: dq448mw7ks) (palivizumab - unii:dq448mw7ks) - synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in pediatric patients: - with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of rsv season, - with bronchopulmonary dysplasia (bpd) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of rsv season, - with hemodynamically significant congenital heart disease (chd) and who are 24 months of age or younger at the beginning of rsv season [see clinical studies (14) ]. limitations of use: the safety and efficacy of synagis have not been established for treatment of rsv disease [see warnings and precautions (5.4)] . synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to synagis [see warnings and precautions (5.1) ]. risk summary synagis is not indicated for use in females of reproductive po

Panama - angļu - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

abbvie ltd. - palivizumab - palivizumab....100.00 mg